Zobrazeno 1 - 10
of 106
pro vyhledávání: '"35"'
Autor:
Jo Anne Zujewski, Jung-Min Lee, John J. Wright, Elise C. Kohn, Nicole D. Houston, Christina M. Annunziata, Anne M. Noonan, Helen X. Chen, John L. Hays, Lori M. Minasian
Publikováno v:
Cancer Research. 73:35-35
Background: Inhibition of the MAPK pathway with sorafenib and neutralization of VEGF with bevacizumab (B) resulted in clinical benefit with interactive toxicity. Dasatinib (D) is a broad spectrum tyrosine kinase inhibitor with high affinity for SRC f
Autor:
Sho Saeki, Akinobu Hamada, Toshiyuki Harada, Satoshi Igawa, Hiroyuki Minemura, Ryo Ko, Shigehiro Yagishita, Takamasa Hotta, Kageaki Watanabe, Satoshi Oizumi, Yuka Fujita, Hidenori Mizugaki, Taichi Takashina
Publikováno v:
Cancer Research. 79:3998-3998
Background: Although reports on the use of gefitinib and erlotinib in elderly patients are occasionally found, reports on afatinib are rare. According to the analysis of 54 Japanese patients in the LUX-Lung3 study, an afatinib dose reduction from 40
Autor:
Maureen E. Trudeau, L.B. Pritzker, Baoqing Guo, Amadeo M. Parissenti, X. Wang, Mu Zhu, Kenneth P.H. Pritzker
Publikováno v:
Cancer Research. 73:P1-08
Background: We recently reported that epirubicin/docetaxel treatment of locally advanced breast cancer patients in the MA.22 clinical trial reduced tumor RNA integrity and that low mid-treatment tumor RNA integrity was associated with a pathologic co
Autor:
E. Alonso, JA Perez-Fidalgo, Begoña Bermejo, Octavio Burgues, Ana Bosch, M Peña-Chilet, Jaime Ferrer, Gloria Ribas, A. Lluch, M. Martinez
Publikováno v:
Cancer Research. 73:P5-13
BACKGROUND AND OBJECTIVES: Breast cancer in very young patients (< 35 years) (BCVY) is an uncommon disease and when it occurs it usually has aggressive biological characteristics. Whether this effect is due to an overrepresentation of aggressive brea
Autor:
David A. Riseberg, Timothy J. Pluard, Shakeela W Bahadur, Lupe G. Salazar, Hope S. Rugo, Seock-Ah Im, William J. Gradishar, Shengyan Hong, Young-Hyuck Im, Trevor M Feinstein, Miguel Henriques Abreu, Antonino Musolino, Edwin P. Rock, Viorela Pop, Fatima Cardoso, Mark D. Pegram, Rossana Berardi, Yelena Novik, Javier Cortes, Giuseppe Curigliano, Serafin Morales Murillo, Kenneth Jacobs, Alfredo Falcone
Publikováno v:
Cancer Research. 81:PS10-24
Background: Margetuximab (M) is an investigational Fc-engineered, anti-HER2 monoclonal antibody with the same epitope specificity as trastuzumab (T). Relative to T, Fc engineering of M increases binding affinity for the activating Fc receptor (FcR) C
Autor:
Shoichi Mizuno, Toshiaki Yoshikawa, Nobuhiro Tsuchiya, Itaru Endo, Tetsuya Nakatsura, Mayuko Yoshimura, Yu Sawada, Kazuya Ofuji, Mari Takahashi, Daisuke Nobuoka
Publikováno v:
Cancer Research. 75:CT115-CT115
Background and purpose: In a phase I trial for advanced hepatocellular carcinoma (HCC), glypican-3(GPC3)-derived peptide vaccination was well-tolerated, and immune responses and antitumor efficacy were noted. The recurrence rates of HCC are still hig
Autor:
Tamaki Yamada, Takashi Joh, Marsha A. Moses, Adelle Dagher, Masahide Ebi, Tomonori Yamada, Takaya Shimjura
Publikováno v:
Cancer Research. 74:892-892
The early diagnosis of gastric cancer (GC) provides the opportunity for curative endoscopic resection. However, although endoscopy is a standard diagnostic method for this disease, comprehensive screening endoscopy would be invasive, expensive and co
Publikováno v:
Cancer Research. 80:P4-12
Background: To analyze the outcomes of breast cancer liver metastasis (BCLM) treated with stereotactic body radiotherapy (SBRT) and systemic treatment. Materials and methods: The treatment outcomes of 33 patients with oligometastasis ( Results: Media
Autor:
Janice M. Walshe, Seamus O'Reilly, William Mullally, Patrick G. Morris, John James Kennedy, Rajnish Gupta, M. Keane, Cathy M. Kelly, Miriam O'Connor, Bryan T. Hennessy, K Duffy, Deirdre O'Mahony, Dara Bracken-Clarke, Andrew Padmore
Publikováno v:
Cancer Research. 80:P3-08
Background: The 21 gene recurrence score (OncotypeDx ®) is reimbursed in Ireland to guide adjuvant treatment decisions for ER+, LN-negative, human epidermal growth factor receptor 2 (HER2)-negative BC. There is emerging evidence supporting the clini
Autor:
Miguel Martín, Janice Lu, J. Wu, Nii Ankrah, Claudio Zamagni, Paul Cottu, Katie Zhou, Michelino De Laurentiis
Publikováno v:
Cancer Research. 80:P1-19
Background: CompLEEment-1 (NCT02941926) is an ongoing phase 3b trial of ribociclib (RIB), a cyclin-dependent kinase 4/6 inhibitor, in combination with letrozole (LET) in patients with hormone receptor-positive (HR+), human epidermal growth factor rec